首页> 外文OA文献 >Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development
【2h】

Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development

机译:人类广泛HIV中和抗体的推定恒河猴猿种系前身:与人类对应物的差异以及对HIV-1疫苗开发的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Broadly neutralizing antibodies (bnAbs) are likely to be a key component of protective immunity conferred by an effective HIV-1 vaccine. We and others have reported that putative human germline predecessors of known human bnAbs lack measurable binding to HIV-1 envelope glycoproteins (Env), which could be a new challenge for eliciting human bnAbs. Rhesus macaques have been used as nonhuman primate models for testing vaccine candidates, but little is known about their germline Abs. Here we show the similarities and differences between putative rhesus macaque and human germline predecessors and possible intermediate antibodies of one of the best characterized bnAbs, b12. Similar to the human counterpart, a putative rhesus macaque b12 germline antibody lacks measurable binding to HIV-1 Envs, suggesting that initiation of somatic maturation of rhesus macaque germline b12 predecessor may also be a challenge. However, differences in sequence characteristics and binding properties between macaque and human b12 germline and intermediate antibodies suggest that the two germline predecessors may undergo different maturation pathways in rhesus macaques and in humans. These results indicate that immunogens that could initiate the immune responses and drive somatic mutations leading to elicitation of b12 or b12-like bnAbs in rhesus macaques and in humans are likely to be different. This has important implications for HIV-1 vaccine development. © 2011 Elsevier Ltd.
机译:广泛中和抗体(bnAbs)可能是有效HIV-1疫苗赋予保护性免疫的关键组成部分。我们和其他人已报道,已知的人类bnAb的假定人类种系前体缺乏与HIV-1包膜糖蛋白(Env)的可测量结合,这可能是引发人类bnAb的新挑战。恒河猴已被用作非人灵长类动物模型来测试候选疫苗,但对其种系Abs知之甚少。在这里,我们显示了假定的恒河猴和人类种系的前身与特征最丰富的bnAbs,b12的可能中间抗体之间的异同。与人类相似,假定的猕猴b12种系抗体缺乏与HIV-1 Envs的可测量结合,这表明猕猴种系b12的前体体细胞成熟的启动也可能是一个挑战。但是,猕猴和人b12种系和中间抗体之间序列特征和结合特性的差异表明,这两种种系的前身在恒河猴和人中可能经历不同的成熟途径。这些结果表明,可以引发免疫反应并驱动体细胞突变导致在恒河猴和人类中引发b12或b12样bnAb的免疫原可能有所不同。这对HIV-1疫苗的开发具有重要意义。 ©2011爱思唯尔有限公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号